Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 16.7B | 13.7% |
| Gross Profit | 12.5B | 32.5% |
| Cost of Revenue | 4.17B | 20.3% |
| Operating expense | 8.93B | 52.8% |
| Net Income | 3.54B | 21.7% |
| EBITDA | 5.65B | 6.1% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 209B | 1.3% |
| Total Liabilities | 116B | 1.2% |
| Total Equity | 92.8B | 4.6% |
| Shares Outstanding | 5.71B | 0.1% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | 4.6B | 890.9% |
| Cash from investing | -2.43B | 161.5% |
| Cash from financing | -2.48B | 22.5% |
EPS
Financial Highlights for Pfizer in Q3 '25
Pfizer reported a revenue of 16.7B, which is a 13.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 12.5B, marking a 32.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 4.17B, a -20.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 8.93B, showing a 52.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 3.54B, showing a 21.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 5.65B, showing a 6.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Pfizer with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
